Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

This article was originally published in The Tan Sheet

Executive Summary

Promotions for Bausch & Lomb's new Ocuvite PreserVision containing vitamins C and E, beta carotene, zinc and copper likely will stress the product's clinically proven eye health benefits.

You may also be interested in...



AREDS-Inspired Study Challenges Omega-3 Cognitive Benefit Claims

Omega-3 supplementation had no impact on cognitive function in a five-year assessment of elderly people participating in AREDS2 research, say NIH researchers. But they add in the JAMA study that longer-term use of omega-3s could result in a different outcome.

AREDS-Inspired Study Challenges Omega-3 Cognitive Benefit Claims

Omega-3 supplementation had no impact on cognitive function in a five-year assessment of elderly people participating in AREDS2 research, say NIH researchers. But they add in the JAMA study that longer-term use of omega-3s could result in a different outcome.

CVS Supplement Deceptively Capitalizes On Proximity To AREDS-Formula Product – Complaint

CVS supplement Advanced Eye Health deceives consumers by piggy-backing off NIH study findings of a Bausch + Lomb formula found to reduce eye disease progression, says a complaint seeking class action status in California state court.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel